<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1025">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147805</url>
  </required_header>
  <id_info>
    <org_study_id>INS1009-202</org_study_id>
    <secondary_id>2021-001528-16</secondary_id>
    <nct_id>NCT05147805</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to assess the effect of treprostinil palmitil inhalation&#xD;
      powder (TPIP) compared with placebo on pulmonary vascular resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 22, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Pulmonary Vascular Resistance at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 6-Minute Walk Test Distance at Week 5, Week 10 and Week 16</measure>
    <time_frame>Baseline and Week 5, Week 10 and Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in 6-Minute Walk Test Distance at Week 5, Week 10 and Week 16</measure>
    <time_frame>Baseline and Week 5, Week 10 and Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Treatment-emergent Adverse Event (AE)</measure>
    <time_frame>Day 1 to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Evaluations</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurements</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change from Baseline in Physical Examinations</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-Dose (AUC24) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-Dose (AUC24) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time 0 to Infinity (AUC∞) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time 0 to Infinity (AUC∞) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time 0 to Last Measurable Concentration (AUClast) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve from Time 0 to Last Measurable Concentration (AUClast) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution After Non-Intravenous Administration (Vd/F) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution After Non-Intravenous Administration (Vd/F) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2) of Treprostinil Palmitil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2) of Treprostinil</measure>
    <time_frame>Day 1 and Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Maximum Plasma Concentration (Rac[Cmax]) of Treprostinil Palmitil</measure>
    <time_frame>Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Maximum Plasma Concentration (Rac[Cmax]) of Treprostinil</measure>
    <time_frame>Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Area Under the Concentration-Time Curve at 24 Hours Post-Dose (Rac[AUC24]) of Treprostinil Palmitil</measure>
    <time_frame>Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Based on Area Under the Concentration-Time Curve at 24 Hours Post-Dose (Rac[AUC24]) of Treprostinil</measure>
    <time_frame>Week 10: Pre-dose and 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Concentration of N-Terminal-Pro Hormone Brain Natriuretic Peptide (NT-proBNP) Levels at Week 5, Week 10 and Week 16</measure>
    <time_frame>Baseline and Week 5, Week 10 and Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Treprostinil Palmitil Inhalation Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered a placebo matching TPIP once per day for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil Palmitil</intervention_name>
    <description>Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.</description>
    <arm_group_label>Treprostinil Palmitil Inhalation Powder</arm_group_label>
    <other_name>INS1009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be ≥ 18 to ≤ 75 years at the time of signing the informed consent&#xD;
             form (ICF). Participants in Japan must be ≥ 20 years of age at the time of signing the&#xD;
             ICF.&#xD;
&#xD;
          -  Participants must have a diagnosis of World Health Organization (WHO) Group 1&#xD;
             Pulmonary Hypertension (PH) (PAH) in any of the following subtypes:&#xD;
&#xD;
               1. Idiopathic&#xD;
&#xD;
               2. Heritable&#xD;
&#xD;
               3. Drug/toxin-induced or connective tissue disease (CTD)-associated PAH&#xD;
&#xD;
          -  PAH diagnosis for at least 1 year.&#xD;
&#xD;
          -  Participants must be on stable PH therapy consisting of up to 2 medications from the&#xD;
             following classes:&#xD;
&#xD;
               1. Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan)&#xD;
&#xD;
               2. Phosphoesterase type 5 inhibitors (eg, sildenafil, tadalafil)&#xD;
&#xD;
               3. Guanylate cyclase stimulator (eg, riociguat)&#xD;
&#xD;
          -  No change in PH medications (eg, ambrisentan, bosentan, macitentan, sildenafil,&#xD;
             tadalafil, riociguat) or dosage for at least 60 days prior to Screening.&#xD;
&#xD;
          -  No change in diuretic use or dosage for at least 30 days prior to Screening.&#xD;
&#xD;
          -  Body Mass Index (BMI) within the range 19.0-32.0 kg/m^2 (inclusive).&#xD;
&#xD;
          -  Male participants: Male participants who are not sterile, with female partners of&#xD;
             childbearing potential, must be using effective contraception from Day 1 to at least&#xD;
             90 days after the last dose of study drug.&#xD;
&#xD;
          -  Female participants: Women must be postmenopausal (defined as no menses for 12 months&#xD;
             without an alternative medical cause), surgically sterile, (ie, post-tubal ligation&#xD;
             for at least 12 months) or using highly effective contraception methods (ie, methods&#xD;
             that alone or in combination achieve &lt;1% unintended pregnancy rates per year when used&#xD;
             consistently and correctly) from Day 1 to at least 90 days after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Male participants with pregnant or non-pregnant woman of childbearing potential&#xD;
             partner must use a condom in order to avoid potential exposure to embryo/fetus.&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF and in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of PH other than idiopathic, hereditary, drug/toxin-induced, or CTD-associated&#xD;
             PAH (eg, congenital heart disease-associated PAH, portal hypertension-associated PAH,&#xD;
             PH belonging to Groups 2 through 5).&#xD;
&#xD;
          -  Allergy, or documented hypersensitivity or contraindication, to TPIP or Treprostinil&#xD;
             or mannitol (an excipient of the TPIP formulation).&#xD;
&#xD;
          -  Any known ventricular or supraventricular tachyarrhythmia except for paroxysmal atrial&#xD;
             fibrillation and any symptomatic bradycardia.&#xD;
&#xD;
          -  History of heart disease including left ventricular ejection fraction (LVEF) ≤ 40% or&#xD;
             clinically significant valvular, constrictive, or symptomatic atherosclerotic heart&#xD;
             disease (eg, stable angina, myocardial infarction, etc).&#xD;
&#xD;
          -  Participation in a cardio-pulmonary rehabilitation program within 1 month of Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Evidence of thromboembolic disease as assessed by ventilation-perfusion (VQ) scan,&#xD;
             pulmonary angiography, or pulmonary computed tomography (CT) scan.&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction.&#xD;
&#xD;
          -  History of HIV infection.&#xD;
&#xD;
          -  Established diagnosis of hepatitis B viral infection, or positive for hepatitis B&#xD;
             surface antigen (HBsAg) at the time of Screening.&#xD;
&#xD;
          -  Established diagnosis of hepatitis C viral infection at the time of screening.&#xD;
&#xD;
          -  Active and current symptomatic coronavirus disease 2019 (COVID-19) or previous severe&#xD;
             disease and/or hospitalization due to COVID-19.&#xD;
&#xD;
          -  Use of live attenuated vaccines within 4 weeks of the Screening Visit.&#xD;
&#xD;
          -  Participants with Down's Syndrome.&#xD;
&#xD;
          -  History of abnormal bleeding or bruising.&#xD;
&#xD;
          -  History of solid organ transplantation.&#xD;
&#xD;
          -  Known or suspected immunodeficiency disorder, including history of invasive&#xD;
             opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis,&#xD;
             coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or&#xD;
             otherwise recurrent infections of abnormal frequency, or prolonged infections&#xD;
             suggesting an immune compromised status, as judged by the Investigator.&#xD;
&#xD;
          -  History of alcohol or drug abuse within 6 months prior to Screening.&#xD;
&#xD;
          -  Acute or chronic impairment (other than dyspnea), limiting the ability to comply with&#xD;
             study requirements, in particular with 6-minute walk test (eg, angina pectoris,&#xD;
             claudication, musculoskeletal disorder, need for walking aids).&#xD;
&#xD;
          -  Participants with current or recent (past 4 weeks) lower respiratory tract infection.&#xD;
&#xD;
          -  History of malignancy in the past 5 years, with exception of completely treated in&#xD;
             situ carcinoma of the cervix and completely treated non-metastatic squamous or basal&#xD;
             cell carcinoma of the skin.&#xD;
&#xD;
          -  Change in PH medication (endothelin receptor agonists, phosphoesterase type 5&#xD;
             inhibitors, and guanylate cyclase stimulators or diuretics) between Screening and&#xD;
             Baseline.&#xD;
&#xD;
          -  Have participated in any other interventional clinical studies within 30 days of&#xD;
             Baseline.&#xD;
&#xD;
          -  Current use of cigarettes (as defined by Centers for Disease Control and Prevention)&#xD;
             or e-cigarettes.&#xD;
&#xD;
          -  Participants who currently inhale marijuana (recreational or medical).&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Insmed Medical Information</last_name>
    <phone>1-844-446-7633</phone>
    <email>medicalinformation@insmed.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treprostinil Palmitil</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

